The U.S. is now facing two intersecting health crises, the ongoing opioid overdose epidemic and the COVID-19 pandemic. Regrettably, each has the potential to exacerbate the effects of the other.
We know that science itself is at its best when it is most inclusive, and humans are best when we embrace diversity. Conversations about systemic racial inequalities can be uncomfortable but are clearly needed.
Today, NIDA issued a Request for Information (RFI) from the research community and any other interested parties regarding the establishment of a standard unit dose of THC in order to facilitate research on cannabis.
Most common mental disorders, from depression and anxiety to PTSD, are associated with disturbed sleep, and substance use disorders are no exception. The relationship may be complex and bidirectional: Substance use causes sleep problems; but insomnia and insufficient sleep may also be a factor raising the risk of drug use and addiction.
Today, NIDA is releasing several new funding opportunity announcements related to the NIH HEAL (Helping to End Addiction Long-term ℠) Initiative.
Ample evidence shows methadone and buprenorphine reduce overdose deaths, prevent the spread of diseases like HIV, and enable people to take back their lives, but there are restrictions on who can prescribe these medications.
This brief fact sheet provides information about why it is important to treat opioid addiction in criminal justice settings and how treatment is being provided.
Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone.
Presents research-based principles of adolescent substance use disorder treatment; covers treatment for a variety of drugs including, illicit and prescription drugs, alcohol, and tobacco; presents settings and evidence-based approaches unique to treating adolescents.
Subscribe to Researchers
This brief fact sheet provides information about the effectiveness of medications for opioid use disorders and recent scientific advances in this area.